It is well-known that tamoxifen increases the risk of endometrial cancer. Although metastasis to the uterus from breast cancer is uncommon, there have been some case reports on uterine metastasis. If an endometrial abnormality is detected, the differential diagnosis of whether the uterine tumor is metastatic or primary is very important to determine the course of treatment. We herein report a case in which we detected a uterine tumor during follow-up after treatment with tamoxifen, and demonstrate that GCDFP-15 is useful in diagnosing metastatic uterine tumors arising from breast cancer
WOS: 000078321800017PubMed ID: 10215447Objective: To investigate the effects of tamoxifen on the end...
Tamoxifen used for adjuvant therapy in breast cancer, has a complex and unclear action on endometriu...
The aim of this retrospective study was to detect endometrial lesions in tamoxifen breast cancer use...
Breast cancer · Uterine metastases · Tamoxifen therapy It is well-known that tamoxifen increases the...
Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer. Despite...
Metastatic carcinoma of the uterus usually originates from other genital sites. Extragenital metasta...
Metastatic carcinoma from extragenital sites to the uterus, particularly the endometrium, is rare an...
Abnormal uterine bleeding is relatively common among patients with history of breast carcinoma and i...
Breast cancer is the most common cancer in women, with a high mortality rate. Genital metastasis of ...
Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer ...
Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-o...
Breast cancer can metastasize to a vast array of organs, but in rare cases cancer can form secondary...
There are few reports of breast cancer cases with uterine metastases. Here, we report a metastatic l...
Background: Breast cancer is not only considered as the most common cancer in women but also is know...
Tamoxifen is a non-steroid estrogenic antagonist, used in post-surgical therapy of breast cancer. It...
WOS: 000078321800017PubMed ID: 10215447Objective: To investigate the effects of tamoxifen on the end...
Tamoxifen used for adjuvant therapy in breast cancer, has a complex and unclear action on endometriu...
The aim of this retrospective study was to detect endometrial lesions in tamoxifen breast cancer use...
Breast cancer · Uterine metastases · Tamoxifen therapy It is well-known that tamoxifen increases the...
Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer. Despite...
Metastatic carcinoma of the uterus usually originates from other genital sites. Extragenital metasta...
Metastatic carcinoma from extragenital sites to the uterus, particularly the endometrium, is rare an...
Abnormal uterine bleeding is relatively common among patients with history of breast carcinoma and i...
Breast cancer is the most common cancer in women, with a high mortality rate. Genital metastasis of ...
Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer ...
Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-o...
Breast cancer can metastasize to a vast array of organs, but in rare cases cancer can form secondary...
There are few reports of breast cancer cases with uterine metastases. Here, we report a metastatic l...
Background: Breast cancer is not only considered as the most common cancer in women but also is know...
Tamoxifen is a non-steroid estrogenic antagonist, used in post-surgical therapy of breast cancer. It...
WOS: 000078321800017PubMed ID: 10215447Objective: To investigate the effects of tamoxifen on the end...
Tamoxifen used for adjuvant therapy in breast cancer, has a complex and unclear action on endometriu...
The aim of this retrospective study was to detect endometrial lesions in tamoxifen breast cancer use...